Core Viewpoint - The 2025 Alumni Conference of Shanghai Jiao Tong University School of Medicine aims to create a platform for emotional connection, resource sharing, and opportunity exchange under the theme "Co-construct, Share, and Co-future" [2]. Agenda Summary - The conference will feature a series of speeches and discussions on various topics related to medical policies, industry opportunities, and advancements in healthcare [3][4]. - Keynote speakers include prominent figures such as Xu Shuqiang, Gu Yan, and Ren Yongqiang, who will address topics like medical policies, obesity treatment, and anti-aging cell therapies [3][4]. - A roundtable discussion will focus on the challenges and strategies for medical companies expanding internationally, featuring industry leaders and experts [4]. Educational Program - The Medical and Health Future Leading Talents program offers a comprehensive curriculum designed to enhance entrepreneurial thinking and strategic capabilities in the healthcare sector [5][6]. - The program emphasizes collaboration between academia and industry, aiming to develop leaders who can navigate complex challenges in the medical field [8][11]. - Participants will engage in workshops and discussions on topics such as innovation in medical products, investment strategies, and the integration of new technologies in healthcare [17][12]. Networking Opportunities - The conference will facilitate networking among alumni, industry leaders, and academic experts, providing a platform for resource matching and innovative collaboration [9][21]. - Attendees will have the chance to visit leading medical institutions and companies, enhancing their understanding of the healthcare ecosystem [21][20]. Alumni Engagement - The alumni association aims to foster a vibrant and innovative community, organizing events that connect scientists and entrepreneurs for knowledge exchange and collaboration [18][19]. - The program includes international study tours to renowned medical institutions, further enriching the learning experience for participants [22][21].

Core Viewpoint - The article discusses an upcoming online and on-site project roadshow organized by SiYu MedTech, focusing on investment opportunities in the biomedical and medical device sectors, emphasizing the importance of founder backgrounds in research or medical fields [1][3]. Group 1: Event Details - The roadshow is scheduled for May 29, 2025, at 14:00, and will take place at the Zhongguancun Medical Device Park [1]. - Registration for the event can be completed through a provided link or by scanning a QR code [2][3]. Group 2: Project Eligibility - Projects eligible for registration range from angel round to C round financing [5]. - The roadshow prioritizes technology transfer projects from hospital doctors and focuses on fields including biomedicine, medical devices, and medical aesthetics [6]. Group 3: Investor Participation - Participating investors are vetted institutions with relevant investment experience [5]. - Projects will have direct access to investors, facilitating efficient communication [5]. Group 4: Follow-up Process - After the roadshow, project teams are encouraged to leave their contact information on their presentations for investors to reach out [7]. - The organization will assist in connecting project CEOs with investors [7]. Group 5: Additional Information - Participation in the roadshow is free, but projects must pass an approval process to be included [11]. - Each session accommodates five projects, and if more than five projects are approved, new applicants will be deferred to the next session [11].

Core Viewpoint - Masimo's financial performance in Q1 2025 showed a significant loss despite revenue growth, leading to a strategic decision to divest its consumer audio business to focus on its core medical technology operations [5][12][14]. Financial Performance - For Q1 2025, Masimo reported a loss of $170.7 million (approximately 1.23 billion RMB), equating to a loss of $3.12 per share, with sales of $372 million, reflecting a 9.5% increase year-over-year [3][4]. - The company's GAAP revenue increased by 10% from Q1 2024, with a gross profit of $234 million and a gross margin of 62.9%, up from 60.8% [4]. - Non-GAAP earnings per share were $1.36, exceeding Wall Street expectations by $0.15, with revenue surpassing the forecast of $367.8 million [5][6]. Future Guidance - For the full year 2025, Masimo expects non-GAAP revenue to be between $1.5 billion and $1.53 billion, representing an 8% to 11% growth at constant currency [6]. - The updated guidance, which includes the impact of new tariffs, projects non-GAAP operating profit between $383 million and $403 million, a 16% to 22% increase year-over-year [8]. Strategic Decisions - Masimo plans to sell its Sound United consumer audio business for approximately $350 million to Harman International, a move aimed at refocusing on its medical technology core [16][18]. - The acquisition of Sound United in 2022 for $1.025 billion did not yield the expected growth, leading to a strategic reevaluation and subsequent divestiture [9][12][14]. Market Context - Sound United, acquired for $1.025 billion, had revenues of approximately $900 million at the time of acquisition, but its revenue declined to $773 million in 2023 [13]. - Analysts suggest that the medical business's gross and operating margins are significantly higher than those of the consumer audio segment, indicating a potential for improved cash flow post-divestiture [14].

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 2025年4月1日， 捷迈邦美 Zimmer Biomet （纽约证券交易所代码：ZBH）宣布，其 RibFix Advantage 固定系统获得了 CE 认证 。据称，这是 首 个 获得 CE 认证的胸内肋骨固定系统。RibFix 提供胸腔镜下肋骨骨折的固定、稳定和融合，相比传统开放复位内固定术，它采用微创方法，可减少软 组织损伤。 # 产品信息 RibFix Advantage 固定系统 的 Advantage Bridge 在拧紧时能适应肋骨的解剖结构并自动贴合，以减少骨折。 系统提供微创植入选项，也可与开放手术方法结合使用，旨在支撑肋骨的自然弧度，以在骨折部位恢复稳定性。该系 统通 过双皮质固定肋骨，无需依赖螺纹与骨骼的啮合。 将钻孔导向器置于期望的位置，使器械的针脚抵住肋骨的上缘。通过钻孔导向器插入直径 4.00 毫米的钻头（麻花钻尖），在骨骼中钻一个 将导管穿过钻孔 ...

Core Viewpoint - The medical device industry in 2024 faces a complex policy environment and market challenges, with a slight revenue growth of 0.19% but a significant decline in net profit by 13.82%, indicating a divergence in performance across different sub-sectors [1][13]. Medical Equipment - The medical equipment sector experienced a revenue decline of 1.38% and a net profit drop of 17.93% in 2024, with Q1 2025 showing a further revenue decrease of 5.27% and a net profit decline of 14.10% [3][10]. - The decline is attributed to slowed bidding processes and inventory digestion, particularly affecting imaging and monitoring equipment [3][4]. - Leading company, United Imaging Healthcare, reported a revenue of 10.3 billion yuan in 2024, a decrease of 9.73%, marking the first decline in net profit in six years [3][4]. High-Value Consumables - The high-value consumables sector saw a revenue growth of 3.58% but a net profit decline of 4.09% in 2024, with Q1 2025 showing a slight revenue increase of 0.25% and a net profit drop of 6.15% [6][7]. - The sector is impacted by price pressures from national procurement policies, but domestic market share for local brands is improving [6][7]. Low-Value Consumables - The low-value consumables sector achieved a revenue growth of 12.86% and a remarkable net profit increase of 114.83% in 2024, with Q1 2025 showing a revenue growth of 2.37% and a net profit growth of 7.19% [8][9]. - The growth is driven by recovery in the domestic market and accelerated international expansion, particularly in mid-to-high-end markets [8][9]. In Vitro Diagnostics - The in vitro diagnostics sector faced a revenue decline of 6.13% and a net profit drop of 47.04% in 2024, with Q1 2025 showing a further revenue decrease of 15.39% and a net profit decline of 40.27% [10][11]. - The decline is largely due to the high base effect from the COVID-19 pandemic and the impact of various policies, including DRGs and procurement policies [10][11]. Conclusion - The overall revenue growth in the medical device industry is stable, but profit volatility is significant, particularly in the in vitro diagnostics and medical equipment sectors. However, growth drivers remain in low-value consumables' international expansion and innovation, high-value consumables' technological updates, and the gradual recovery of medical equipment [13][14].

2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 # 财报数据 2024年澳华内镜实现营业 收入7.50亿元 ，同比 增长10.54% 。这一增长主要得益于公司在海外市场的布局 和产品准入的推进，海外销售收入达到1.6亿元，同比 增长42.7% 。 2024年 归属于上市公司股东的净利润为 2,101.22 万元 ， 同比下降63.68% ，归属于上市公司股东的扣 除非经常性损益的净利润-628.61万，同比下降114.13%。 公司经营活动产生的现金流量净额为-7892.83万元，较上年同期 下降311.01% 。全年销售费用为2.50亿， 研发费用为1.64亿。 # 投资者关系活动记录 近日， 澳华内镜 发布了2024年全年年报， 并于2025年5月9日发布 《投资者关系活动记录表》 公告。 | | | | 里\/: 兀 | 巾秤:人民巾 | | --- | --- | --- | --- | --- | | 主要会计数据 ...

Core Viewpoint - The article discusses the leadership transition at Intuitive Surgical, highlighting the achievements of outgoing CEO Gary Guthart and the incoming CEO Dave Rosa, while also addressing the company's evolution and future challenges in the medical robotics industry [2][5][7]. Group 1: Leadership Transition - Gary Guthart has served as CEO of Intuitive Surgical since 2002, leading the company from an annual revenue of less than $100 million to $8.35 billion in 2024 [2][5]. - Dave Rosa, who joined the company in 1996 and has held various key positions, will take over as CEO on July 1, 2025, marking a natural succession in leadership [6][7]. Group 2: Company Evolution - Under Guthart's leadership, Intuitive Surgical expanded its product offerings, market reach, and business model, establishing a comprehensive ecosystem that includes devices, consumables, and services [4][5]. - The company has installed over 10,000 surgical systems globally and has performed more than 17 million surgeries to date [5]. Group 3: Future Challenges - The leadership change occurs as Intuitive Surgical faces a new cycle characterized by increased competition in the medical robotics field, slower procedure expansion, stricter regulations, and heightened efficiency demands [7]. - Analysts suggest that Rosa's extensive product experience and systemic understanding will help maintain strategic coherence and enhance organizational efficiency in the face of these challenges [7].

为展示心血管科技创新成果，汇聚跨界交流动能，2025年5月15日， 全球心血管大会（Global Cardiovascular Conference 2025） 在北京召开。来自临床一线、科研院所、产业前沿和投资机构的 500余位专业人士到场参会，现场气氛热烈、交流充分。会上，重磅揭晓 全球心血管医疗科技创新系列奖 项（Global Cardiovascular Awards 2025） ，集中展示当前中国心血管器械领域的技术突破与发展活 力。 大会现场，海淀区副区长林航、北京市医药健康科技发展中心主任刘慧，给获奖企业颁发了获奖证书。 获奖名单如下（排名不分先后）。 10家 2025全球 心血管技术创新奖 阿迈特医疗 获奖理由： 北京阿迈特医疗器械有限公司是全球领先的 采用3D多轴精密打印（3D MAP）技术进行 可降解血管支架等创 新植介入器械 研发和生产的 国家高新技术企业。公司已有三款III类医疗器械上市销售，另有有三款III类医疗 器械进入国家创新医疗器械特别审查程序。其中 3D打印可降解冠脉和外周血管药物洗脱支架已进入随机对照 临床研究阶段 ，阶段性临床结果令人满意。另一个III类创新器械"医用二氧 ...

Core Viewpoint - Embecta reported a decline in revenue for Q2 2025, primarily due to the termination of its insulin patch pump project and a strategic shift towards the rapidly growing GLP-1 market [1][6][10]. Financial Performance - Q2 2025 revenue was $259 million (approximately 1.87 billion RMB), a year-over-year decrease of 9.8%, with a constant currency decline of 7.7% [2][3]. - Net income for the quarter was $23.5 million, down 18.7% year-over-year, attributed to reduced revenue and increased restructuring costs [2]. - Revenue breakdown showed a significant decline in pen needles by 13.7% to $188.3 million, while syringes decreased by 4.0% to $28.8 million [3][4]. - Safety devices saw a slight increase of 2.7% to $34.2 million, and contract manufacturing revenue surged by 69.2% to $4.4 million [4]. Insulin Patch Pump Project Termination - The insulin patch pump project, aimed at developing systems for type 2 diabetes, was terminated in November 2024 due to competitive pressures and the rise of GLP-1 drugs [7][9]. - The termination is expected to incur restructuring costs between $35 million to $45 million, including cash and non-cash asset impairments [9]. - This decision is projected to save the company $60 million to $65 million annually, allowing a focus on core business and growth opportunities [9]. Strategic Shift to GLP-1 Market - The GLP-1 receptor agonist market is anticipated to reach $109 billion by 2030, prompting Embecta to explore opportunities in this area [10]. - The company began developing GLP-1 drug delivery solutions in September 2023, launching a small packaging GLP-1 needle in Germany in December 2024 [10]. - Embecta aims to expand its market share through partnerships with generic drug companies, expecting continued growth in the GLP-1 sector [10]. Company Overview - Embecta specializes in innovative insulin delivery and disease management solutions for diabetes patients, having become an independent Nasdaq-listed company in 2022 [11]. - The company’s core products include pen needles, syringes, and safety injection devices, serving approximately 30 million diabetes patients globally [11].

Core Viewpoint - The approval of the Aortic Arch Stent System by Xianjian Technology marks a significant advancement in the treatment of aortic diseases, particularly for Stanford type B aortic dissections, addressing a critical unmet medical need in the market [1][3][4]. Product Development Background - Aortic endovascular intervention has gained recognition among clinicians and is in a rapid development phase, with approximately 70% of aortic dissection cases involving the ascending aorta and aortic arch [3]. - The complexity of the aortic arch anatomy has historically posed challenges for endovascular treatment, particularly in reconstructing the three branch arteries [3]. - Xianjian Technology's Aortic Arch Stent System, designed for chimney and fenestration techniques, aims to provide effective treatment solutions for patients with aortic arch lesions [3][4]. Product Introduction - The Aortic Arch Stent System is a collaborative innovation between Professor Shuchang's team and Xianjian Technology, having entered the special approval process for innovative medical devices in October 2022 [4]. - The system consists of the Ankura™ Plus Aortic Arch Main Stent System and the CSkirt™ Aortic Arch Branch Stent System, designed to facilitate the creation of a "window" for blood flow during surgery [4][5]. Clinical Trial Data - The prospective, multi-center clinical trial for the Aortic Arch Stent System involved over 30 authoritative centers, with 10 cases completed in the First in Man (FIM) study showing no complications such as vascular rupture or death [9][10]. - The trial included 120 patients, achieving an immediate surgical success rate of 97.46% and a 12-month treatment success rate of 90.83% [10]. Competitors in the Market - Competitors include InnoVascular with the Quick Fenestrater system, which is also designed for aortic arch branch artery reconstruction [11]. - Other notable players include Huamai Technology, Medtronic, Gore, and JOTEC GmbH, each offering various stent systems with unique features and applications in aortic arch treatment [11][13][15][16]. Company Overview - Xianjian Technology, established in 1999 and listed on the Hong Kong Stock Exchange in 2011, focuses on the research, production, and sales of cardiovascular and peripheral vascular interventional medical devices [16]. - As of June 30, 2024, the company has achieved a high-quality patent portfolio with 2,198 patents and has had 15 products approved for the special review process by the National Medical Products Administration (NMPA) [16][20].